Occam Places CEO for RadioPharm Start-Up
ARTBIO was founded by Roy Larsen, PhD inventor of the technology behind the breakthrough radiotherapeutic cancer drug, Xofigo. Occam placed Emanuele Ostuni, PhD the former head of Novartis Oncology's cell and gene therapy unit in Europe, as CEO.
The global start-up with offices in Oslo, London, Basel, and Boston just emerged from stealth with a robust pipeline and $23M from an international syndicate of investors, including F-Prime Capital and Omega Funds.
ARTBIO's board includes Ted Love, CEO of Global Blood Therapeutics until its $5.4B acquisition by Pfizer, and Susanne Schaffert, former President of Novartis Oncology. ARTBIO's lead asset in prostate cancer entered the clinic and will be developed quickly alongside other internal pipeline programs.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.